FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CTATEMENIT	UE CHYNCES	IN BENEFICIAL	UNVIEDCHID
SIAILIVILIVI	OF CHANGES		OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Georgantas Robert William III				2. Issuer Name and Ticker or Trading Symbol BIODESIX INC [BDSX]					(Che	ck all applica	Director		erson(s) to Issuer 10% Owner Other (specify		
LDERNES	•	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/23/2021						_ x	X below) Chief Scientific Officer				
		80301 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)						
1. Title of Security (Instr. 3) 2. Transa Date			Transacti	action 2A. Deemed Execution Date,		3. 4. Securities Acquired (A)		(A) or	5. Amoun Securities Beneficia Owned Fo	s Ily ollowing	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
				Code V Amount (A) or (D)				Price	Transacti	ion(s)		((Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
Conversion Date Execution Execution (Month/Day/Year) if any			Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		Amount of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
\$0.77	02/23/2021		A		2,843 ⁽¹⁾⁽²⁾		(1)(2)	04/14/2030	Common Stock	2,843	\$0	2,843	3	D	
\$0.77	03/10/2022		A		2,842 ⁽¹⁾⁽³⁾		(1)(3)	04/14/2030	Common Stock	2,842	\$0	5,685	5	D	
	(F LDERNES 00 ER C (S Security (Inst	(First) LDERNESS PLACE 00 (State) Ta Security (Instr. 3) 2. (State) Conversion or Exercise Price of Derivative Security \$0.77 02/23/2021	(First) (Middle) LDERNESS PLACE 00 ER CO 80301 (State) (Zip) Table I - Non-D Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security \$0.77 02/23/2021 \$0.77 03/10/2022	(First) (Middle) LDERNESS PLACE 00 ER CO 80301 (State) (Zip) Table I - Non-Derivativ Security (Instr. 3) Table II - Derivativ (e.g., put: (Month/Day/Year) Price of Derivative Security 2. Conversion or Exercise (Month/Day/Year) Price of Derivative Security A \$0.77 02/23/2021 A \$0.77 03/10/2022 A	Table II - Derivative Security (Instr. 3) Table II - Derivative Security (Instr. 3) Table II - Derivative Security (Month/Day/Year) Table II - Derivative Security (Month/Day/Year)	Solution Solution	Security (Instr. 3) Security (Instr. 3)	### BIODESIX INC [BDSX] ### BIODESIX INC [BD	BIODESIX INC BDSX BIODESIX INC BDSX State BIODESIX INC BIODESIX INC	Security (Instr. 3) Securities Securit	BIODESIX INC BDSX	Security (Instr. 3) Securities Securit	BIODESIX INC BDSX	BIODESIX INC BDSX	Security (Instr. 3) Securities Acquired (A) or Person Date (Month/Day/Year) Date (Month/Day/Ye

- 1. On April 15, 2020, the Reporting Person was granted an option to purchase 5,685 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years.
- 2. On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 2,843 shares underlying the option.
- 3. On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 2,842 shares underlying the option.

/s/ Robin H. Cowie as Attorneyin-Fact for Robert Georgantas 03/18/2022 \underline{III}

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.